GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT)

GSA Capital Partners LLP lowered its holdings in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 30.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 339,595 shares of the company's stock after selling 148,530 shares during the quarter. GSA Capital Partners LLP owned approximately 0.48% of Altimmune worth $2,085,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ALT. CANADA LIFE ASSURANCE Co purchased a new stake in Altimmune during the first quarter valued at approximately $44,000. TFO Wealth Partners LLC purchased a new stake in shares of Altimmune during the first quarter valued at $51,000. Horizon Wealth Management LLC purchased a new position in shares of Altimmune during the 2nd quarter valued at approximately $66,000. PFG Investments LLC purchased a new stake in shares of Altimmune in the second quarter valued at about $67,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Altimmune during the 2nd quarter valued at approximately $70,000. 78.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on ALT shares. UBS Group initiated coverage on shares of Altimmune in a research note on Tuesday. They issued a "buy" rating and a $26.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, August 22nd. B. Riley reiterated a "buy" rating and set a $20.00 price objective on shares of Altimmune in a report on Monday, August 12th. Finally, Evercore ISI raised shares of Altimmune to a "strong-buy" rating in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $20.00.

Altimmune Stock Performance

NASDAQ:ALT traded up $0.03 on Wednesday, reaching $9.52. The stock had a trading volume of 10,019,999 shares, compared to its average volume of 3,858,755. Altimmune, Inc. has a 12-month low of $2.34 and a 12-month high of $14.84. The company has a 50-day moving average of $6.89 and a 200 day moving average of $6.87.

Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 52.60% and a negative net margin of 199,076.92%. During the same quarter last year, the company posted ($0.39) earnings per share. On average, research analysts expect that Altimmune, Inc. will post -0.54 earnings per share for the current fiscal year.

Insider Transactions at Altimmune

In related news, Director David Drutz sold 16,011 shares of the company's stock in a transaction on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the transaction, the director now directly owns 41,958 shares in the company, valued at $289,510.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.10% of the company's stock.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.